Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity

NCT07170319 is registered in ClinicalTrials.gov with Innovent Biologics Technology Limited (Shanghai R&D Center) as lead sponsor.

NCT NCT07170319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07170319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After Multiple Ascending Doses in Participants With Overweight or Obesity
Lead sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 25, 2025
Completion date
March 31, 2026
Enrollment
79 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight or obesity